Recent innovations across the multiple ADC components, such as enhanced antibody-targeting to the tumors, better linker ...

Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

NextCure has ramped up its antibody-drug conjugate (ADC) pivot, penning a $745 million deal for the ex-China rights to ...

ADC Therapeutics (NYSE:ADCT), on Thursday, reported results from an early stage trial testing its antibody drug conjugate, ...

Global Antibody Drug Conjugate Market is valued at approximately USD 5.60 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.12% over the forecast period 2024-2030.

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

NextCure is joining the China biopharma gold rush, partnering with Simcere Pharmaceutical Group on development of a novel ...

Orion Corporation has broadened its partnership with Glykos, focusing on the development of antibody-drug conjugates (ADCs).

In a prostate cancer mouse model (22Rv1 xenografts), the combination of 225 Ac-YS5 (0.12 µCi) + YS5-MMAE (1.8 mg/kg) was associated with the most significant reduction in tumor volume (green curves in ...

Erika Hamilton, MD, discusses the mechanism of action of emiltatug ledadotin, a B7-H4-directed Dolasynthen antibody-drug conjugate.